Brind.
  1. Vertex and AbCellera are collaborating to advance T cell therapies (TCEs) for autoimmune diseases.

AbCellera announced that its Phase II clinical trial data exceeded expectations for blockbuster potential on August 11, 2026.

1 report, 1 independent Updated Aug 11
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

AbCellera announced that its Phase II clinical trial data exceeded expectations for blockbuster potential on August 11, 2026.

Who's involved

What this event is mainly about

Keep exploring

The entities involved

  • AbCellera

    company in Vancouver, Canada

    Nothing else this week.

Coverage

Newest first; wire copies grouped